While the original rationale for anti-TNF treatment was to intervene in the lung pathology, more recent insights suggest that specific groups of patients, in particular COPD patients with cachexia may benefit from TNF-blocking agents (Rennard et al., 2013). This evidence concerns the gene TNF and chronic obstructive pulmonary disease.